Shandong Xinhua Pharmaceutical Co Ltd: A Snapshot of Recent Performance
Shandong Xinhua Pharmaceutical Co Ltd, a prominent player in the health care sector, has recently been in the spotlight due to its performance on the Hong Kong Stock Exchange. As of May 15, 2025, the company’s close price stood at HKD 6.21. This figure is part of a broader trend observed over the past year, where the company’s stock price reached a 52-week high of HKD 8.05 on October 7, 2024, and a 52-week low of HKD 5 on September 15, 2024.
The company, headquartered in Shandong Province, China, is renowned for its specialization in the development, manufacturing, and marketing of bulk pharmaceutical products. Its product range includes antipyretic, analgesic, antiseptic, and central nervous system medicines, catering to a wide array of medical needs.
With a market capitalization of HKD 8,120,000,000, Shandong Xinhua Pharmaceutical Co Ltd maintains a price-to-earnings ratio of 8.59, reflecting its financial health and investor confidence. The company has been publicly traded on the Hong Kong Stock Exchange since its initial public offering in December 1996.
For those interested in learning more about Shandong Xinhua Pharmaceutical Co Ltd and its offerings, additional information is available on their official website at www.xhzy.com .
As the company continues to navigate the competitive landscape of the pharmaceutical industry, its strategic focus on key product areas and its established market presence position it as a significant entity within the health care sector.